Business Context and Reporting Period
This Form 6-K filing by MDxHealth SA covers the month of May 2024. The company, a foreign private issuer based in Herstal, Belgium, reports on significant financing activities and the filing of unaudited interim condensed financial statements for the three months ended March 30, 2024.
Key Financial Metrics and Capital Structure
The filing details a new senior secured credit facility and an equity offering program rather than providing specific revenue or profit figures for the period.
- Credit Facility: A five-year facility with an aggregate principal amount of up to $100 million.
- Initial Drawdown: $55 million advanced on May 1, 2024.
- Future Availability: $25 million available by March 31, 2025, and $20 million by March 31, 2026, subject to net revenue requirements.
- Interest Rate: SOFR or 2.50% (whichever is greater) plus 8.50%.
- Liquidity Covenant: Requirement to maintain unrestricted cash and cash equivalents between $5 million and $20 million.
- Equity Offering: A Sales Agreement for an "at-the-market" offering of up to $50.0 million in ordinary shares.
- Warrants: Issuance of warrants to subscribe for up to 1,243,060 ordinary shares at an exercise price of $2.41 per share.
Material Changes Versus Prior Period
The primary material change is the establishment of the new debt and equity financing structures on May 1, 2024, and April 30, 2024, respectively. The filing does not provide comparative financial data (revenue, profit, or cash flow) for the three months ended March 30, 2024, to assess operational changes versus prior periods; it only references the filing of these statements as an exhibit.
Outlook, Risks, and Contingencies
Management Commentary and Covenants: The Credit Agreement imposes strict covenants. If net revenue does not meet minimum amounts in any quarter, the company must begin repaying the principal in equal monthly installments plus a premium. The agreement also restricts the ability to incur additional debt, pay dividends, or dispose of assets.
Risks and Contingencies:
- Default Triggers: Events of default include nonpayment, material adverse effects, loss of key permits, and change of control.
- Acceleration: Upon an event of default, the full outstanding amount becomes immediately due with a repayment premium.
- Equity Dilution: The issuance of warrants and potential share sales under the Sales Agreement may dilute existing shareholders.
- Shareholder Approval: The warrant issuance is subject to approval by an extraordinary general shareholders' meeting.
Investor Verification Checklist
- Verify the specific net revenue thresholds required to avoid mandatory principal repayment under the Credit Agreement.
- Confirm the status of the extraordinary general shareholders' meeting required to approve the warrant issuance.
- Review the unaudited interim condensed financial statements (Exhibit 99.1) for actual revenue, net loss, and cash position for the quarter ended March 30, 2024.
- Assess the impact of the 8.50% margin over SOFR on future interest expense.
- Monitor the company's unrestricted cash balance to ensure compliance with the $5 million to $20 million minimum requirement.